Company news

Longeveron Inc. news in 2026

Longeveron Inc.'s news releases, calls and decks from 2026, newest first.

View company

Longeveron Announces Engagement of Lucid Capital Markets

October 28, 2026

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

October 26, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

September 30, 2026

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

September 16, 2026

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

August 19, 2026

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

August 12, 2026

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

August 11, 2026

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

August 3, 2026

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

July 23, 2026

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

July 13, 2026

Longeveron® Appoints Marie Washburn as Chief Financial Officer

July 6, 2026

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

June 9, 2026

Longeveron to Present at BIO International Convention 2026

June 3, 2026

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

May 20, 2026

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

May 13, 2026

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

May 10, 2026

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

May 8, 2026

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

May 5, 2026

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

April 7, 2026

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

March 16, 2026

Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

March 12, 2026

Longeveron Announces Closing of Private Placement of up to $30 Million

March 10, 2026

Longeveron Announces Private Placement of up to $30 Million

March 9, 2026

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

February 25, 2026

Longeveron Appoints Stephen H. Willard as Chief Executive Officer

February 16, 2026

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

February 13, 2026

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

February 5, 2026

Longeveron Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells

January 30, 2026

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

January 29, 2026

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

January 26, 2026

Calls in 2026

Decks in 2026